Vanguard Group Inc Neurocrine Biosciences Inc Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
638Shares Held
93.8MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.15 Billion0.04% of portfolio
-
State Street Corp Boston, MA5.15MShares$782 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$391 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$283 Million3.62% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$282 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...